

Patent Application
Attorney Docket No.PC10834ATMC

a¹
cont
agonist, a galanin antagonist, a bombesin agonist, a neuropeptide-Y antagonist, a thyromimetic agent, dehydroepiandrosterone or an analog thereof, a glucocorticoid receptor agonist or antagonist, an orexin receptor antagonist, a urocortin binding protein antagonist, a glucagon-like peptide-1 receptor agonist, or a ciliary neurotrophic factor.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

Claims 1-16 are pending in the present application.

Claims 1-16 are subject to a restriction and/or election requirement.

Attached hereto is a marked-up version of the change made to Claim 11 by the current amendment. The attached page is captioned **"VERSION WITH MARKINGS TO SHOW CHANGES MADE"**. Subject matter that was deleted is in brackets. Subject matter that was added is underlined.

The Examiner has interpreted Claim 11 as being directed to a pharmaceutical composition rather than a method; this interpretation is based on Claim 11's dependence from and further limiting of Claim 9. Applicant would agree that Claim 11 was intended to be directed to a pharmaceutical composition and was inadvertently written as a method claim. With the above amendment, Claim 11 has been rewritten as a pharmaceutical composition claim. Support for this amendment is in the specification as filed and would be readily apparent to one of ordinary skill in the art. No new matter is added to this application with this amendment, and its entry is respectfully requested.

ELECTION/RESTRICTIONS

The Examiner has required restriction to one of the following inventions under 35 USC 121:

Group I. -- Claims 1 (in part), 2 (in part), 5 (in part), 7 and 8 drawn to a method of administering neurotensin-1 agonist to a patient who is, or is at risk of becoming obese, classification dependent on agent structure;

Group II. -- Claims 1, 2 and 6 (each in part) drawn to a method of administering neurotensin-1 antagonist to a patient who is, or is at risk of becoming obese, classification dependent on agent structure;